AETERNA genetics published results on its lead anti cancer agent Perifosine at American Association for cancer research annual meeting

Current article ratings:
Patients / public:5 (1 votes)healthcare Prof:
AETERNA genetics Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that two posters on his leadership of anti cancer agent, Perifosine, on the 102nd Annual meeting of the American Association for cancer research currently held at the Orange County Convention Center in Orlando presented wurdenFlorida.

Poster # 1965:

With the title "anti tumor activity of novel Act inhibitor, Perifosine in the stomach of cell lines", Tae-Soo Kim, Kim Hyo song, Bo RAM Kwan, Chan Hee Park, Hei-Cheul CHEUNG, Woo ick Jang, Jürgen Engel, Hyun cheol Chung, Jae Kyung Roh, Sun young RHA, (Yonsei cancer CenterYonsei University College of medicine, Seoul, Korea).

Results

Perifosine single-agent showed anti-proliferative activity in a variety of gastric cancer cell lines. Perifosine 8 / 13 cell lines resistant to 5-FU showed a synergistic Antiproliferative activity with 5-FU. 72% Of the cell lines of the Pact were discovered high basal levels. The treatment with Perifosine significantly reduced tumor growth in nude mice inoculated with the YCC 2 subcutaneous gastric cancer cell line. Finally a MTT conducted based microarray analysis, identify pharmacogenomic classifications for synergy in 5-FU resistant to cell lines.

Conclusions

Perifosine demonstrates antitumor activity in multiple gastric cancer cell lines. Perifosine improves the antitumor activity of 5-FU in parts of the cell lines - including 5-FU cell lines also constantly. 5-FU is the active metabolite of the prodrug Xeloda, which is advanced approved for the treatment of stomach cancer in many countries such as Japan and Korea.

Poster # 640:

With the title "the Act inhibitor Perifosine greatly increased the antivascular and antitumor activity of CD34 + cells developed to express membrane-bound tumor necrosis factor related apoptosis inducing ligand (TRAIL)" , Arianna Giacomini, Silvia L. Locatelli, Marco Righi, Loredana Cleris, Paolo D. Longoni, Marco Milanesi, Maura FrancoliniMichele Magni, Massimo di Nicola, Alessandro M. Gianni, Carmelo Carlo Stella (medical oncology, Fondazione IRCCS Istituto Nazionale Tumori Milano and University of Milan, Milan, Italy).

Results

Pro-apoptotic TRAIL receptors in tumor cells available are known to be a potential pharmaceutical target for cancer treatment. Perifosine stimulates the expression of Pro-apoptotic TRAIL receptors on the cell line reducing the levels of Phosphorylated Act multiple myeloma/plasmacytoma KMS-11, and significantly improved the sensitivity of these cells to trail-induced apoptosis. The same molecular effects were noted in the non-Hodgkin's lymphoma cell line SU-DHL-4V. In this line TRAIL resistant cell Perifosine treatment significantly enhanced cytotoxicity TRAIL treatment to similar levels in the TRAIL to see sensitive multiple myeloma cell line.

The synergistic activity confirmed NOD/SCID mice Xenograft models, where Perifosine is a down-modulation of the Act of expression, as well as TRAIL receptor Upregulation in tumor cells and endothelial cells induced tumor.

Conclusion

Perifosine significantly improves the antitumor activity of cellular TRAIL based treatment and TRAIL resistance in vitro and in vivo could overcome. The results are in line with other studies show the synergistic effects of Perifosine with cytostatic drugs, including bortezomib and 5-FU.

Jürgen Engel, PhD. AETERNA genetics President and CEO, commented: "Stomach cancer poses a significant threat in Asia." The potential of Perifosine shows this preclinical work especially in combination with Xeloda for the treatment of stomach cancer. "In addition are both posters in line with previous data and the clinical observations stressed the benefits of the combination of Perifosine with cytostatic drugs in various oncological indications."

About Perifosine

Perifosine activation of Phosphoinositide 3-kinase (PI3-k) inhibits way is a novel, oral anti-cancer treatment, the Act. The product by interfering with membranes of cancer cells which in turn signal which works then concerns Act cell death, growth, differentiation and survival. Perifosine, in combination with chemotherapy, is currently investigated for the treatment of multiple myeloma, colorectal cancer and other cancers, and is the most advanced cancer agent of his class. Perifosine, is as a single agent, studied in other indications. US Food & Drug Administration ("FDA") granted Perifosine orphan drug status in multiple myeloma and neuroblastoma, and fast-track names in multiple myeloma and refractory advanced colorectal cancer. In addition, an agreement with the FDA to carry out the phase 3 studies in both made this information under a special protocol assessment. Perifosine was granted also orphan medicinal product designation from the European Medicines Agency ("EMA") in multiple myeloma. In addition Perifosine received expected positive scientific advice from the EMA for the multiple myeloma and metastatic colorectal cancer programs, ongoing phase 3 trials for these indications, to be sufficient for the registration in Europe. Perifosine have rights to keryx Biopharmaceuticals for North America, Yakult Honsha for Japan and Handok for Korea was licensed.

Source:
AETERNA genetics Inc.

See drug information on Xeloda.